Luspatercept increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study

Platzbecker, U., Germing, U., Giagounidis, A., Goetze, K., Kiewe, P., Mayer, K., Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Radsak, M., Wolff, T., Haase, D., Hankin, M., Wilson, D., Zhang, X., Laadem, A., Sherman, M. and Attie, K. 2015. Luspatercept increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study. Leukemia Research 39 (S1) , S25. 10.1016/S0145-2126(15)30054-0

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Elsevier
ISSN:	0145-2126
Last Modified:	02 Nov 2022 09:54
URI:	https://orca.cardiff.ac.uk/id/eprint/96777

Actions (repository staff only)

Edit Item